GlobeNewswire: ARTIS Ventures Contains the last 10 of 13 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:19:53ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/12/2808745/0/en/Leading-TechBio-Investment-Firm-ARTIS-Ventures-Announces-2023-Class-of-Healthcare-and-Life-Sciences-Fellows.html?f=22&fvtc=4&fvtv=21083Leading TechBio Investment Firm ARTIS Ventures Announces 2023 Class of Healthcare and Life Sciences Fellows2024-01-12T17:00:00Z<![CDATA[New class includes a diverse range of expertise, including biophysics, cardiology, ophthalmology, bioengineering, cancer biology, and more New class includes a diverse range of expertise, including biophysics, cardiology, ophthalmology, bioengineering, cancer biology, and more ]]>https://www.globenewswire.com/news-release/2023/07/12/2703384/0/en/Delivering-Next-Generation-Addiction-Recovery-Affect-Therapeutics-Raises-16-Million-in-Series-A-Funding-Led-by-ARTIS-Ventures.html?f=22&fvtc=4&fvtv=21083Delivering Next Generation Addiction Recovery, Affect Therapeutics Raises $16 Million in Series A Funding Led by ARTIS Ventures2023-07-12T11:00:00Z<![CDATA[Smartphone app for drug and alcohol addiction offers a portable, personalized and effective digital treatment program to help break the addiction cycle Smartphone app for drug and alcohol addiction offers a portable, personalized and effective digital treatment program to help break the addiction cycle]]>https://www.globenewswire.com/news-release/2023/06/12/2686486/0/en/With-the-Potential-to-Revolutionize-Personalized-Health-Range-Biotechnologies-Receives-5-2-Million-in-Seed-Funding-Led-by-TechBio-Focused-ARTIS-Ventures.html?f=22&fvtc=4&fvtv=21083With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures 2023-06-12T15:00:00Z<![CDATA[Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics]]>https://www.globenewswire.com/news-release/2022/12/14/2573912/0/en/Leading-TechBio-Investment-Firm-ARTIS-Ventures-Announces-2022-Class-of-Healthcare-and-Life-Sciences-Fellows.html?f=22&fvtc=4&fvtv=21083Leading TechBio Investment Firm ARTIS Ventures Announces 2022 Class of Healthcare and Life Sciences Fellows2022-12-14T16:00:00Z<![CDATA[2022 annual class will support investment team and portfolio companies while gaining valuable venture capital experience 2022 annual class will support investment team and portfolio companies while gaining valuable venture capital experience ]]>https://www.globenewswire.com/news-release/2022/10/10/2531188/0/en/ARTIS-Ventures-Welcomes-Henry-Klingenstein-to-Its-Investment-Team.html?f=22&fvtc=4&fvtv=21083ARTIS Ventures Welcomes Henry Klingenstein to Its Investment Team2022-10-10T15:00:00Z<![CDATA[Pioneering TechBio investment firm expands with recent Stanford Graduate School of Business MBA, Computational Medicine Co-founder Pioneering TechBio investment firm expands with recent Stanford Graduate School of Business MBA, Computational Medicine Co-founder]]>https://www.globenewswire.com/news-release/2021/12/15/2352909/0/en/ARTIS-Ventures-Promotes-Ameena-El-Bibany-to-Partner.html?f=22&fvtc=4&fvtv=21083ARTIS Ventures Promotes Ameena El-Bibany to Partner 2021-12-15T15:40:51Z<![CDATA[San Francisco, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- ARTIS Ventures, a San Francisco-based venture firm focused on pioneering investments at the intersection of life sciences and computer sciences, today announced Ameena El-Bibany has been named partner where she will continue to help early stage teams translate their research from academia to industry.]]>https://www.globenewswire.com/news-release/2021/08/03/2274021/0/en/ARTIS-Ventures-Announces-2021-Class-of-Healthcare-and-Life-Sciences-Fellows.html?f=22&fvtc=4&fvtv=21083ARTIS Ventures Announces 2021 Class of Healthcare and Life Sciences Fellows 2021-08-03T17:13:20Z<![CDATA[ARTIS Fellows will support the investment team and be given the opportunity to work directly with impactful healthcare startups, to learn about new cutting-edge technologies on the TechBio frontier, and to gain VC experience during a record-setting market ARTIS Fellows will support the investment team and be given the opportunity to work directly with impactful healthcare startups, to learn about new cutting-edge technologies on the TechBio frontier, and to gain VC experience during a record-setting market]]>https://www.globenewswire.com/news-release/2021/03/31/2202456/0/en/Creating-Next-Generation-Smart-Cell-Therapies-Outpace-Bio-Receives-30-Million-in-Series-A-Funding-Led-by-ARTIS-Ventures-and-Lyell-Immunopharma-Inc.html?f=22&fvtc=4&fvtv=21083Creating Next Generation Smart Cell Therapies: Outpace Bio Receives $30 Million in Series A Funding Led by ARTIS Ventures and Lyell Immunopharma Inc.2021-03-31T13:00:00Z<![CDATA[Outpace seeks to dramatically improve the efficacy and safety of cell and gene therapies; announces collaboration with Lyell Outpace seeks to dramatically improve the efficacy and safety of cell and gene therapies; announces collaboration with Lyell]]>https://www.globenewswire.com/news-release/2020/07/07/2058768/0/en/Second-Front-Systems-Raises-6-Million-to-Provide-Immediate-Impact-to-National-Security-led-by-ARTIS-Ventures.html?f=22&fvtc=4&fvtv=21083Second Front Systems Raises $6 Million to Provide Immediate Impact to National Security, led by ARTIS Ventures2020-07-07T15:00:00Z<![CDATA[As the U.S. military embraces commercial tech, including AI, biotech, and cyber, Second Front to create a new business operating system for the Department of Defense As the U.S. military embraces commercial tech, including AI, biotech, and cyber, Second Front to create a new business operating system for the Department of Defense]]>https://www.globenewswire.com/news-release/2020/04/20/2018772/0/en/ARTIS-Ventures-Welcomes-Jeff-Kindler-as-Operating-Partner.html?f=22&fvtc=4&fvtv=21083ARTIS Ventures Welcomes Jeff Kindler as Operating Partner 2020-04-20T16:00:00Z<![CDATA[Centrexion Therapeutics CEO, Former Pfizer CEO, Brings Decades of Business Experience to Firm Centrexion Therapeutics CEO, Former Pfizer CEO, Brings Decades of Business Experience to Firm ]]>